ES2813877T3 - Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos - Google Patents

Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos Download PDF

Info

Publication number
ES2813877T3
ES2813877T3 ES14840944T ES14840944T ES2813877T3 ES 2813877 T3 ES2813877 T3 ES 2813877T3 ES 14840944 T ES14840944 T ES 14840944T ES 14840944 T ES14840944 T ES 14840944T ES 2813877 T3 ES2813877 T3 ES 2813877T3
Authority
ES
Spain
Prior art keywords
expression profile
panel
subject
multikinase inhibitor
gene markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14840944T
Other languages
English (en)
Spanish (es)
Inventor
Sheng Guo
Dawei Chen
Juan Zhang
Jie Cai
Henry Qixiang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Bioscience Inc Taicang
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Application granted granted Critical
Publication of ES2813877T3 publication Critical patent/ES2813877T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES14840944T 2013-08-28 2014-08-28 Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos Active ES2813877T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013082487 2013-08-28
PCT/US2014/053142 WO2015031604A1 (en) 2013-08-28 2014-08-28 Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same

Publications (1)

Publication Number Publication Date
ES2813877T3 true ES2813877T3 (es) 2021-03-25

Family

ID=52587328

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14840944T Active ES2813877T3 (es) 2013-08-28 2014-08-28 Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos

Country Status (9)

Country Link
US (1) US11136625B2 (enExample)
EP (1) EP3039424B1 (enExample)
JP (1) JP6612232B2 (enExample)
CN (1) CN105659085B (enExample)
CY (1) CY1123415T1 (enExample)
DK (1) DK3039424T3 (enExample)
ES (1) ES2813877T3 (enExample)
PT (1) PT3039424T (enExample)
WO (1) WO2015031604A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
JP6853789B2 (ja) * 2015-12-24 2021-03-31 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
EP3906031A4 (en) * 2019-01-02 2022-10-05 Zhejiang Crownmab Biotech Co. Ltd. CANCER TREATMENT USING A MULTI-TARGET KINASE INHIBITOR IN COMBINATION WITH PROTEIN KINASE BIOMARKERS
CN111521810B (zh) * 2019-02-02 2024-06-21 中国科学院上海药物研究所 癌症患者根据脾酪氨酸激酶进行分层
CN111693707A (zh) * 2020-07-16 2020-09-22 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断血管炎患者中的应用
CN118345086B (zh) * 2024-04-22 2024-10-11 西部(重庆)科学城种质创制大科学中心 柑橘溃疡病抗性Cs7g24050基因及其编码蛋白与应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
ES2267605T3 (es) 1999-12-22 2007-03-16 Sugen, Inc. Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa.
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2400070T3 (es) 2001-12-03 2013-04-05 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
SE0104164L (sv) 2001-12-11 2003-06-12 Ericsson Telefon Ab L M Högspännings-mos-transistor
NO317200B1 (no) 2002-08-09 2004-09-13 Best Practice Deployment As System for trafikkopplaering i et kjoretoy
WO2004029287A2 (en) 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
GB0411378D0 (en) 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007047955A2 (en) 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP1954272A2 (en) 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
EP2049084A2 (en) 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
RU2009114745A (ru) * 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
AU2008279027B8 (en) * 2007-07-25 2014-03-06 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
US20090062347A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched axitinib
US20090062368A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
NZ583790A (en) 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
WO2009054004A2 (en) 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
US20100256392A1 (en) 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (en) 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
AU2009215377A1 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009106825A1 (en) 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
EP2098521A1 (en) 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009111061A1 (en) 2008-03-06 2009-09-11 Sicor Inc. Process for the preparation of sorafenib and salts thereof
CA2720164A1 (en) 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
US8501962B2 (en) 2008-06-23 2013-08-06 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
WO2010011834A2 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
US20110301113A1 (en) 2008-09-26 2011-12-08 Concert Pharmaceuticals Inc. Pyridineamine derivatives
KR20100051769A (ko) 2008-09-30 2010-05-18 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 베이스 및 ｌ-말산의 비정질 조성물
CA2741087A1 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2366162A1 (en) * 2008-11-18 2011-09-21 Collabrx, Inc. Individualized cancer treatment
WO2010135608A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
JP2012533562A (ja) 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
CN102665756A (zh) 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法
WO2011047019A1 (en) * 2009-10-13 2011-04-21 Yale University An objective, quantitative method to predict histological subtype in non-small cell lung cancer
WO2011050159A1 (en) 2009-10-23 2011-04-28 Glaxo Wellcome Manufacturing Pte Ltd Compositions and processes
UY33164A (es) 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
TW201206908A (en) 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
WO2011146458A1 (en) 2010-05-18 2011-11-24 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
ES2643851T3 (es) 2010-11-01 2017-11-24 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Procedimientos para la preparación de 3-((pirrol-2-il)metilen)-2-pirrolonas usando 2-sililoxi-pirroles
WO2012073254A1 (en) 2010-11-29 2012-06-07 Hetero Research Foundation A process for the preparation of pazopanib using novel intermediate
EP2654797B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2012103060A1 (en) 2011-01-27 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
WO2012116040A1 (en) * 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
CN102283836B (zh) * 2011-06-27 2013-01-09 苏州大学附属第一医院 索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
WO2013043529A1 (en) 2011-09-19 2013-03-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
US20140322166A1 (en) * 2011-12-12 2014-10-30 Stc. Unm Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
US20140087362A1 (en) * 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same

Also Published As

Publication number Publication date
US20160208328A1 (en) 2016-07-21
US11136625B2 (en) 2021-10-05
JP2016528914A (ja) 2016-09-23
EP3039424B1 (en) 2020-07-29
CN105659085B (zh) 2018-12-07
DK3039424T3 (da) 2020-08-31
JP6612232B2 (ja) 2019-11-27
WO2015031604A1 (en) 2015-03-05
CN105659085A (zh) 2016-06-08
PT3039424T (pt) 2020-09-03
EP3039424A4 (en) 2017-03-29
CY1123415T1 (el) 2021-12-31
EP3039424A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
ES2813877T3 (es) Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
Suh et al. Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas
CN109890982B (zh) 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
Domínguez-Soto et al. Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis
US20140005070A1 (en) Markers associated with cyclin-dependent kinase inhibitors
HK1255495A1 (en) Method for selecting personalized tri-therapy for cancer treatment
WO2006054129A1 (en) Improved treatment of cancer by double-stranded rna
EP2640860A2 (en) Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
KR102194746B1 (ko) Wnt 억제제와 연관된 마커
CN104703620A (zh) 诊断和治疗方法
US20210177844A1 (en) Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
WO2014028222A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
Rink et al. Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population
Fialka et al. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early-and late-stage oral squamous cell carcinoma–a pilot study
Kim et al. Phase II clinical trial of eribulin–gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma
Chiu et al. Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma
WO2016189282A1 (en) Method for treatment and prognosis of colorectal cancer
Sirek et al. Expression profile of messenger and micro RNAs related to the histaminergic system in patients with five subtypes of breast cancer
Tutusaus et al. GAS6/TAM axis as therapeutic target in liver diseases
Jacobse et al. Eosinophils exert direct and indirect anti-tumorigenic effects in the development of esophageal squamous cell carcinoma
許哲源 PTEN loss is a possible mechanism of trastuzumab resistance in extramammary Paget disease [an
ES2395881T3 (es) Marcador predictivo para el tratamiento de inhibidor de EGFR
Huang et al. Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation
Cornea The Role of BRK in Gastric Cancer
Bai et al. GRHL3 specifically initiated by the TP63 transcription factor promotes the metastasis of squamous cell carcinogenesis